Invictus MD Strategies Corp. GENE:CA IVITF is pleased to announce that its wholly-owned subsidiary, Acreage Pharms Ltd. (“Acreage Pharms”), has successfully completed testing on two batches of oil and is working to finalize its application to Health Canada to allow for the sale of bottled cannabis oil and cannabis resin.

Acreage Pharms’ closed-loop CO2 system performs Subcritical and Supercritical Fluid Extraction utilizing high-pressure carbon dioxide to extract essential oils from botanicals, using specific temperatures and pressures to withdraw different components from plants. The system is operating at full capacity to build inventory in anticipation of Acreage Pharms receiving Health Canada approval. The new product line is expected to include a 1-to-1 ratio of CBD to THC oil, high CBD oil, and high THC oil for both the medial and recreational markets.

“We are expanding our portfolio to satisfy consumer demand, adding oils and concentrates to our line-up of premium flower products,” said George E. Kveton, CEO of Invictus. ” Research shows oils are increasing in popularity and we need to remain nimble to keep abreast of market trends.”

Separately, Invictus has also granted 150,000 stock options to a certain advisor of the Company. Each stock option has an exercise price of $0.98 and is exercisable into one common share of the Company. The options vest immediately and are exercisable over a period of five years. The stock options were granted subject to the terms and conditions of the Company’s Stock Option Plan.

In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.